Amgen ends marketing agreement with GSK for osteoporosis drug
(Reuters) - Amgen Inc said it was ending an agreement with GlaxoSmithKline Plc, under which the British company marketed Amgen's postmenopausal osteoporosis drug in some regions outside the United States.
No comments:
Post a Comment